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Abstract
Objective
High concentrations of leukocytes in blood have been associated with diabetes mellitus.
This prospective study aimed to explore whether total and differential leukocyte counts are
associated with incidence of diabetes. A missense variant R262W in the SH2B3 (SH2B
adaptor protein 3) gene, coding for a protein that negatively regulates hematopoietic cell
proliferation, was also studied in relation to incidence of diabetes.
Methods and Results
Leukocyte count and its subtypes (neutrophils, lymphocytes and mixed cells) were ana-
lyzed in 26,667 men and women, 45–73 years old, from the population-based Malmö Diet
and Cancer study. Information about the R262W polymorphism (rs3184504) in SH2B3 was
genotyped in 24,489 subjects. Incidence of diabetes was studied during a mean follow-up
of 14 years. Cox proportional hazards regression was used to examine incidence of diabe-
tes by total and differential leukocyte counts. Mendelian randomization analysis using
R262W as an instrumental variable was performed with two-stage least squares regression.
A total of 2,946 subjects developed diabetes during the follow-up period. After taking sev-
eral possible confounders into account, concentrations of total leukocyte count, neutrophils
and lymphocytes were all significantly associated with incidence of diabetes. The adjusted
hazard ratios (95% confidence interval; quartile 4 vs quartile 1) were 1.37 (1.22–1.53) for
total leukocytes, 1.33 (1.19–1.49) for neutrophils and 1.29 (1.15–1.44) for lymphocytes. The
R262W polymorphism was strongly associated with leukocytes (0.11x109 cells/l per T
allele, p = 1.14 x10-12), lymphocytes (p = 4.3 x10-16), neutrophils (p = 8.0 x10-6) and mixed
cells (p = 3.0 x10-6). However, there was no significant association between R262W and
fasting glucose, HbA1c or incidence of diabetes.
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Conclusions
Concentrations of total leukocytes, neutrophils and lymphocytes are associated with inci-
dence of diabetes. However, the lack of association with the R262W polymorphism sug-
gests that the associations may not be causal, although limitations in statistical power and
balancing pleiotropic effects cannot be excluded.
Introduction
Inflammation has been repeatedly associated with diabetes mellitus, both in cross-sectional
and prospective studies [1–5]. A meta-analysis of 20 prospective cohorts and cross-sectional
studies found that raised leukocyte concentrations are associated with higher risk of type 2 dia-
betes [3]. However, results were inconsistent across studies [2–4, 6, 7], and the authors pointed
out that results from the meta-analysis likely represent an overestimate due to publication bias
and inability to control for potential confounders in all studies [3]. Most studies are cross-sec-
tional and few prospective studies have examined the role of leukocytes in the development of
diabetes. The Atherosclerosis Risk in Communities (ARIC) study from the USA found elevated
leukocyte count to be associated with development of diabetes among 12,330 non-diabetic
individuals aged 45–64 years after a mean follow-up of 7 years [2]. The National Health and
Nutrition Examination Survey Epidemiologic Follow-up Study (NHEFS) found leukocyte
count to be significantly and positively related to diabetes incidence with a dose-response rela-
tionship [6]. A high leukocyte count was found to predict impaired glucose tolerance and type
2 diabetes in Pima Indians [4]. In the Cardiovascular Health Study (CHS), only C-reactive pro-
tein (CRP) and not leukocyte count was associated with the development of diabetes [7].
Since gene variants are inherited and usually not subject to confounding [8], it is possible to
use genetic polymorphisms as instrumental variables (IV) to explore the relationship between
a trait and a certain outcome, without confounding bias from measured and unmeasured risk
factors. We used a missense polymorphism (R262W, SNP rs3184504) in the SH2B adaptor
protein 3 (SH2B3) gene to examine the effect of leukocyte count on diabetes. The R262W poly-
morphism is known to be associated with increased concentrations of leukocytes and its sub-
populations [9, 10]. The SH2B3 gene codes for a protein that negatively regulates the hemato-
poiesis in knock-out models [11]. Loss of function of SH2B3 has been identified as a risk factor
for leukemia [12].
The aim of this prospective study was to explore the relationship between total and differen-
tial leukocyte count and incidence of diabetes in an urban population.
Subjects and Methods
Study population
The population-based cohort Malmö Diet and Cancer study (MDC), from the city of Malmö
in southern Sweden, was used in this study [13, 14]. In brief, all women born between 1923 and
1950 and men born between 1923 and 1945 living in Malmö city were invited to the MDC
study during the period March 1991 to September 1996. A total of 30 447 individuals partici-
pated in clinical examinations at the screening center and filled in a self-administered question-
naire out of an eligible population of74 000 individuals http://atvb.ahajournals.org/content/
32/2/533.long-ref-17#ref-17. DNA was available for 28 767 subjects.
Subjects with history of diabetes (n = 1 311) at the baseline examination were excluded. In
order to exclude individuals with severe inflammation, analyses were restricted to participants
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with information on total leukocyte counts less than 20.0 × 109 cells/L [15]. In addition, 888
participants without complete information on covariates were excluded. Thus, the final study
population in the project consisted of 26 667 subjects (10 364 men (38.9%) and 16 303 women
(61.1%), aged 45–73 years. A random subsample from the MDC cohort, the MDC cardiovascu-
lar cohort (MDC-CV, n = 6,103), was invited to take part in a study of the epidemiology of
carotid artery disease between October 1991 and February 1994 [16]. The additional examina-
tions in this sub-cohort included measurements of fasting whole blood glucose, hemoglobin
A1c (HbA1c) and CRP.
The ethics committee at Lund University Lund, Sweden, approved the study (LU 51/90)
and all participants provided informed written consent.
Baseline examinations
The examinations were performed by trained nurses at the screening center. Blood pressure
(mmHg) was measured using a mercury-column sphygmomanometer after 10 minutes of rest
in the supine position. Standing height (m) was measured with a fixed stadiometer calibrated
in centimeters. Weight was measured to the nearest 0.1 kg using balance-beam scale with sub-
jects wearing light clothing and no shoes. Body mass index (BMI) was calculated as weight (kg)
divided by the square of the height (m2). Waist was measured as the circumference (cm)
between the lowest rib margin and iliac crest.
Information on family history of diabetes, current use of lipid-lowering, blood pressure-
lowering or anti-diabetic medications, smoking habits, leisure-time physical activity, education
level and marital status were obtained from a self-administered questionnaire [13]. Family his-
tory of diabetes was defined as known diabetes in at least one first-degree relative [17]. History
of myocardial infarction or stroke at the baseline examination was retrieved from the Swedish
Hospital Discharge Register and the Stroke register in Malmö [18, 19]. Subjects were catego-
rized into current smokers (i.e. those who smoked regularly or occasionally) or non-smokers
(i.e. former smokers and never smokers). Low level of leisure-time physical activity was defined
as the lowest quartile of a score revealed through 18 questions covering a range of activities in
the 4 seasons. The evaluation of the questionnaire has been previously reported [20]. Educa-
tional level was divided into three groups: school year<9, 9–12 and> 12, respectively [21].
Marital status was categorized into married or not.
Laboratory measurements
Total and differential leukocyte counts (neutrophils, lymphocytes, and a group of mixed cell
types including monocytes, eosinophils and basophils) were counted in heparinized blood
samples using a SYSMEX K1000 automatic counter (Sysmex Europe, Norderstedt, Germany).
The analyses were performed consecutively at the time of the screening examination, at the
central laboratory of Malmö University Hospital.
HbA1c and whole blood glucose was measured according to standard procedures at the
Department of Clinical Chemistry. HbA1c was measured by ion exchange chromatography,
with reference values of 3.9–5.3% in non-diabetic individuals. Insulin was measured by a radio-
immunoassay in mIU/ L and the HOMA index was calculated as fasting insulinglucose/22.5
[16]. CRP was analyzed using a high-sensitive assay, Tina-quant1 CRP latex assay (Roche
Diagnostics, Basel, Switzerland).
Incidence of diabetes. All subjects were followed from the baseline examination until first
diagnosis of diabetes, death, emigration from Sweden or December 31st, 2009, whichever came
first. Cases of new-onset diabetes in the MDC cohort were identified from several sources [22,
23]. In short, incident diabetes was identified from the Malmö HbA1c register (MHR) (56% of
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all cases), the Swedish National Diabetes Register (NDR) (14%), the Swedish inpatient register
(40%), the Swedish outpatient register (38%), the nationwide Swedish drug prescription
register (65%) and the regional Diabetes 2000 register of the Skåne region (22%) [22, 23].
In addition, 44% of cases were identified at re-examinations of the cohort [24]. At least two
independent sources confirmed the diagnosis for 71.6% of the cases, and 53% of cases were
identified in three independent data sources. NDR and the Diabetes 2000 register required a
physician´s diagnosis according to established diagnostic criteria (fasting plasma glucose con-
centration of> = 7.0 mmol/L, which corresponds to a fasting whole blood glucose of> = 6.1
mmol/L, measured on 2 different occasions). The MHR at the Department of Clinical Chemis-
try, Malmö University Hospital, analyzed and recorded all HbA1c samples taken in institu-
tional and non-institutional care in the greater Malmö area from 1988 onwards. Individuals
who had at least two HbA1c recordings> = 6.0% in the MHR with the Swedish Mono-S stan-
dardization system (corresponding to 7.0% according to the US National Glycohemoglobin
Standardization Program) after the baseline examination were defined as incident diabetes
cases.
Polymorphism in the SH2B3 gene
The missense polymorphism R262W (rs3184504), which previously has been associated with
concentrations of leukocytes, neutrophils and lymphocytes [9, 10] was genotyped in 24,489
subjects. Based on results from previous GWAS studies of leukocyte count in subjects with
European ancestry [25–27], we also tested whether polymorphisms in the 17q21 locus
(rs4065321, rs3859192, rs9916158, rs4794822 and rs17609240) were useful as instrumental
variables in this study. These genotypes were studied in relation to leukocyte count in a sub-
sample of 4600 individuals, but none of the SNPs from the 17q21 locus reached p<0.5 x10-8
for the association with leukocyte count. Since we also found a significant inverse relationship
between insulin resistance and the 17q21 locus, both in the literature [28] and in our data, we
decided to use the R262W polymorphism only.
DNA was extracted from peripheral blood cells and assigned to batches without regard to
disease status or personal identity. Batches were genotyped using real-time polymerase chain
reaction (PCR) with 2.5 ng DNA as PCR template for allelic discrimination on an ABI7900HT
(Life Technologies, Carlsbad, CA, USA). Genotype calls were obtained using SDS 2.3 software
(Life Technologies, Carlsbad, CA, USA) with manual inspection and curation of fluorescence
intensity plots. The call rate was>90%. The Hardy-Weinberg equilibrium (HWE) was calcu-
lated using an online calculator (chi-2 = 3.42, df = 2, p = 0.06).
Statistical analysis
Subjects were categorized into sex-specific quartiles of leukocyte concentrations, i.e., four
groups with the same proportion of men and women in each group. One-way analysis of vari-
ance (ANOVA) and logistic regression was used to assess cross-sectional relationships of leu-
kocyte count to diabetes risk factors. A general linear model was used to adjust glucose and
HbA1c for potential confounding factors, in categories of the R262W polymorphism. Cox pro-
portional hazards regression was used to examine hazard ratios (HR) with 95% confidence
interval (CI) for incidence of diabetes by total and differential leukocyte counts (neutrophils,
lymphocytes, and mixed cells) using the lowest quartile as the reference category. Time axis
was follow-up time until death, emigration, incident diabetes or end of follow-up. The results
were adjusted for age, sex, BMI and family history of diabetes in the basic model [17, 29]. Sec-
ondly, we also adjusted for waist circumference, systolic blood pressure, using of blood pres-
sure- or lipid-lowering medication, history of cardiovascular disease, smoking habits, leisure
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physical activity, educational level andmarital status. CRP was added to the covariates in an addi-
tional analysis in the MDC-CV sub-cohort. Possible interaction between leukocyte count and
risk factors for diabetes was explored by introducing interaction terms in the fully adjusted multi-
variate model. The Kaplan-Meier curve was used to demonstrate incidence of diabetes in relation
to total leukocyte count during the follow-up. The association between leukocyte count, fasting
blood glucose and HbA1c, respectively, was analyzed using general linear model adjusted for age,
sex and BMI. Model discrimination was estimated with Harrell’s C-statistics [30].
Sensitivity analyses were performed after excluding individuals having a cold or lung infec-
tion within two weeks before the baseline examination. We also explored the effect of non-ste-
roid anti-inflammatory drug (NSAID) medication on the relationships between leukocytes and
diabetes.
A Mendelian randomization analysis path diagram was presented in Fig 1. R262W was used
as an instrumental variable for leukocyte count to study incidence of diabetes. Mendelian ran-
domization analysis was performed with two-stage least squares regression (2SLS) using the
ivreg2 command in STATA [31]. The genetic instrument was validated for association with
total and differential leukocyte counts using linear or logistic regression models. A power anal-
ysis was performed for the association between R262W and incidence of diabetes. With α =
0.05, there was 64% power to detect a significant relationship, assuming a HR of 1.25 per stan-
dard deviation increment of leukocytes, i.e., the age and sex-adjusted HR in the present cohort.
All analyses were performed using IBM SPSS statistics (version 20; IBM Svenska AB, Stock-
holm, Sweden) and STATA12 (Stata Corp, College Station, TX, USA).
Results
Baseline Characteristics
The mean total leukocyte count was 6.37±1.68 x109 /L, and the proportion of neutrophils, lym-
phocytes, and mixed cells were 61%, 31% and 8%, respectively. The relationships between sex-
specific quartiles of total leukocyte count and risk factors for diabetes are presented for all sub-
jects in Table 1, and separately for men and women in S1 Table and S2 Table. Increased leuko-
cyte count was associated with age, BMI, waist circumference, systolic blood pressure,
antihypertensive- or lipid-lowering medication, prevalent cardiovascular disease, smoking hab-
its, low physical activity, education level and being married. In addition, HbA1c, glucose and
insulin were positively and significantly associated with leukocyte count (p<0.001) in the sub-
group, Table 1.
Incidence of diabetes in relation to total and differential leukocyte counts
During a mean follow-up of 14 years, 2 946 subjects (1 521 men and 1 425 women, 7.87 per
1000 person-years) developed diabetes. Kaplan-Meier curves of diabetes free survival in
Fig 1. The Mendelian randomization path diagram. The relationship between the instrumental variable
R262W, leukocytes (exposure variable), confounding factors and the outcome diabetes.
doi:10.1371/journal.pone.0148963.g001
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relation to sex-specific quartiles of total leukocyte count is shown in Figs 2 and 3. Incidence of
diabetes was significantly associated with total and differential leukocyte counts in the basic
model 1, Table 2. After adjustment for potential confounding factors, the association remained
significant for total leukocyte (4th vs 1st quartiles HR: 95% CI; 1.37; 1.22–1.53), neutrophil
(1.33; 95% CI: 1.19–1.49) and lymphocyte (1.29; 95% CI: 1.15–1.44) counts, but not for mixed
cells (1.04; 95% CI: 0.94–1.15, not shown in table). Male sex, family history of diabetes, high
BMI and waist circumference, high systolic blood pressure, use of antihypertensive and lipid-
lowering medications, current smoking and low education level were all significantly associated
with incidence of diabetes in the final multivariate model. No significant interaction was
observed between total leukocyte count and other risk factors for diabetes. Use of non-steroid
anti-inflammatory drugs (NSAID) (n = 822) at baseline was added to the multivariable
adjusted model in a sensitivity analysis, but the results were essentially unchanged. NSAID was
not a significant risk factor for diabetes in the model.
We also performed a sensitivity analysis after excluding individuals who reported having a
cold or lung infection within two weeks before the baseline examination (n = 20 906). After
adjustment for potential confounding factors, the association remained significant for total
Table 1. Quartiles of total leukocytes and diabetes mellitus risk factors of participants in MDC (n = 26 667) and MDC-CV (n = 5 473).
MDC (N = 26 667)
Sex-speciﬁc quartiles Q1 Q2 Q3 Q4 p
N (men/women) 2575/4246 2548/4097 2712/3790 2529/4170
Leukocyte count, Men median (P25—P75), (10
9/L) 4.70(4.20–5.20) 5.60(5.40–5.90) 6.60(6.40–6.90) 8.30(7.60–9.10)
Leukocyte count, Women median (P25—P75) (10
9/L) 4.70(4.0–5.00) 5.70(5.40–5.90) 6.70(6.50–7.00) 8.30(7.70–9.10)
Sociodemographic variables
Age (years) 57.6±7.0 58.4±7.7 58.4±7.7 57.8±8.0 <0.001
Married (%) 68.9 66.3 66.1 59.8 <0.001
Low education (%) 37.8 41.0 42.3 45.6 <0.001
Anthropometric measurements
Waist circumference (cm) 81.6±15.3 83.5±12.6 85.0±16.0 85.0±13.2 <0.001
BMI (kg/m2) 25.0±3.5 25.7±3.8 25.9±4.0 26.0±4.2 <0.001
Medical history variables
Family history of diabetes, (%) 2.0 2.0 1.8 1.7 0.226
Prevalent cardiovascular disease (%) 1.7 2.4 3.2 3.6 <0.001
Systolic blood pressure (mmHg) 138±19 141±20 142±20 143±20 <0.001
Antihypertensive medication (%) 12.2 15.8 18.4 21.3 <0.001
Lipid-lowing medication (%) 2.1 2.9 3.1 3.2 <0.001
Lifestyle variables
Current smoker (%) 13.1 19.6 30.0 51.2 <0.001
Low physical activity (%) 20.8 22.5 24.3 28.5 <0.001
MDC-CV Subcohort (n = 5 473)
N (men/women) 508/768 643/883 508/762 586/815
Leukocyte count, median, (men/women) (109/L) 4.30/4.30 5.40/5.40 6.40/6.40 7.90/7.80
Glucose (mmol/L) (n = 5082) 4.87±0.55 5.01±0.85 5.02±0.71 5.07±0.80 <0.001
HbA1c (%) (n = 5082) 4.70±0.40 4.79±0.49 4.84±0.51 4.97±0.55 <0.001
Insulin* (mIU/l) (n = 4912) 6.00(4.00–8.00) 7.00(4.00–9.00) 7.00(5.00–10.00) 7.00(4.75–10.00) <0.001
CRP* (mg/L) (n = 4904) 0.90(0.50–1.80) 1.30(0.70–2.50) 1.50(0.80–3.10) 2.20(1.00–4.30) <0.001
All values are mean±SD, unless otherwise stated.
*insulin, CRP is presented as median and interquartile limits, due to skewed distribution. P value for log-transform value.
MDC, Malmö Diet and Cancer.
doi:10.1371/journal.pone.0148963.t001
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leukocyte (4th vs 1st quartiles HR: 1.39; 95% CI; 1.22–1.58), neutrophil (1.37; 95% CI: 1.21–
1.56) and lymphocyte (1.32; 95% CI: 1.16–1.50) counts, while mixed cells remained non-signif-
icant (1.03; 95% CI: 0.92–1.16).
In the MDC-CV subcohort, 736 subjects developed diabetes during the follow-up. The HR
(95% CI) for total leukocyte count (4th vs 1st quartile) was 1.95 (1.55–2.46, P for trend<0.001)
in the basic model, S3 Table. The HR was reduced to 1.53 (1.20–1.95; P for trend 0.004) taking
possible confounders into account and remained significant also after adding CRP into the
model (HR: 1.37; 1.05–1.77; P for trend 0.044). Among the leukocyte subpopulations, only neu-
trophils remained significantly associated with incidence of diabetes after adjustment for CRP
(HR: 1.39; 1.08–1.78, P for trend 0.022), S3 Table.
The C-statistics value for a model with age, sex and BMI was 0.717 (0.708–0.726) and
increased to 0.722 (0.713–0.731) when leukocyte count was added to the model. Leukocyte
count significantly improved the discriminatory value (C-statistic) for incidence of diabetes
with 0.005 (0.002–0.008) (p<0.001).
Polymorphism in the SH2B3 gene
The association between the R262W polymorphism and leukocyte count is shown in Table 3.
The frequency of the minor allele (T) of R262W was 48%. The T allele was strongly associated
with increased leukocytes (0.11x109 cells/l per T allele, p = 1.14 x10-12, F statistics = 50.6), lym-
phocytes (p = 4.3 x10-16), neutrophils (p = 8.0 x10-6) and mixed cells (p = 3.0 x10-6). There was
no association between the R262W polymorphism and BMI (p = 0.154), waist (p = 0.495), sys-
tolic blood pressure (p = 0.231) and use of lipid-lowering medication (p = 0.723).
We found no statistically significant association between the R262W polymorphism and
incidence of diabetes, fasting blood glucose or HbA1c, Table 3. These relationships remained
non-significant after full adjustment for potential confounding factors in multivariable Cox
regression (diabetes) or general linear models (glucose, HbA1c) (all p>0.288). For glucose, the
IV estimator was -0.210 (95% CI: -0.723–0.302) (p = 0.421); for HbA1c, the IV estimator was -0.201
(-0.558–0.157) (p = 0.272). For diabetes, the IV estimator was -0.005 (-0.047–0.057)(p = 0.837).
Fig 2. Diabetes mellitus free survival in relation to quartiles of total leukocytes in men.
doi:10.1371/journal.pone.0148963.g002
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Discussion
The present study showed a graded association between concentrations of leukocytes, neutro-
phils and lymphocytes and risk of developing diabetes among middle-aged subjects, taking
many potential confounding factors into account. The results confirm that leukocyte count is a
risk factor for incidence of diabetes. However, a missense polymorphism in the SH2B3 gene,
strongly associated with leukocyte count, was not related to glucose, HbA1c or incidence of dia-
betes. This suggests that the relationship between leukocytes and diabetes might not be causal.
Previous studies have reported that various inflammation markers, e.g., interleukin-6,
tumor necrosis factor α (TNFα) and CRP are associated with diabetes [1, 2, 32] It is believed
that TNFα contributes to diabetes through its interaction with insulin signaling pathways and
beta-cell function [33]. Since human granulocytes secrete TNFα, this could be a possible link
between leukocyte count and diabetes [34]. A polymorphism in the IL-6 gene has been associ-
ated with total and differential white blood cell counts [35]. Since IL-6 is produced by human
mononuclear cells, this suggests that IL-6 might be a common link between leukocyte count
and diabetes [36]. Hence, the relationship between leukocytes and diabetes could be related to
the actions of various pro-inflammatory cytokines.
Observational studies could be limited by unmeasured confounding. However, as the alleles
are randomly assigned at meiosis and fixed through the lifetime, genetic association studies are
usually not subject to confounding. The R262W polymorphism, which is a non-synonymous
SNP located in exon 3 of SH2B3, leads to an amino acid change in the pleckstrin homology
domain. SH2B3 regulates cytokine receptor-mediated signaling implicated in leukocyte activa-
tion [37, 38]. The R262W polymorphism was strongly associated with leukocyte count (F sta-
tistics value = 50.6), but we did not find any association between R262W and diabetes, glucose
or HbA1c. The results indicate that the relationship between leukocytes and diabetes might not
be causal. However, it should be acknowledged that the leukocyte population is highly complex
with many different subpopulations [10]. It remains possible that specific populations of leuko-
cytes could be causally associated with diabetes. In addition, even though the number of partic-
ipants was high and the SNP can be considered a fairly strong instrument, it is still possible
Fig 3. Diabetes mellitus free survival in relation to quartiles of total leukocytes in women.
doi:10.1371/journal.pone.0148963.g003
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that the statistical power was too small in this study. The minor allele of the R262W polymor-
phism has been previously associated with increased risk of several autoimmune diseases
including type 1 diabetes [39], multiple sclerosis [40], blood pressure [41] and MI [9]. Some of
these disorders could increase the probability that diabetes is detected and that antihyperten-
sive treatments are prescribed that could increase blood glucose levels. It is not possible to
exclude the possibility of pleiotropic effects. However, a potential relationship between the
minor allele and increased risk of type 1 diabetes, MI and hypertension should increase the risk
of diabetes and cannot explain the negative results in this study.
Strength and limitations
The strength of the study was the large numbers of subjects and events during a long follow-up
period. A limitation of the present study is lack of information on type of diabetes. Participants
were 45–73 years old and non-diabetic at the baseline examination. It can be assumed that
almost all incident cases developed type 2 diabetes, since type 1 diabetes usually has an early
onset, and were excluded from analyses as prevalent cases [42]. New cases of diabetes were
identified from several independent sources. The registers of out- and in-patients cover all
Table 2. Incidence of diabetes mellitus in relation to sex-specific quartiles of total and differential leukocyte counts in MDC cohort (N = 26 667).
MDC (N = 26 667)
Sex-speciﬁc quartiles Q1 Q2 Q3 Q4 p for trend
Leukocyte count
Incident diabetes, (men/women) (n/n) 305/249 369/324 405/346 442/506
All1 1.00 1.17(1.05–1.31) 1.26(1.13–1.41) 1.72(1.54–1.91) <0.001
All 2 1.00 1.08(0.97–1.21) 1.12(0.99–1.25) 1.37(1.22–1.53) <0.001
Men 1 1.00 1.11(0.95–1.29) 1.17(1.01–1.36) 1.54(1.33–1.79) <0.001
Men2 1.00 1.03(0.88–1.20) 1.05(0.90–1.23) 1.26(1.08–1.47) 0.003
Women1 1.00 1.24(1.05–1.46) 1.39(1.18–1.64) 1.97(1.69–2.30) <0.001
Women2 1.00 1.14(0.97–1.35) 1.21(1.02–1.42) 1.53(1.30–1.79) <0.001
Neutrophils
Incident diabetes, (men/women) (n/n) 303/233 398/345 370/373 450/474
All 1 1.00 1.22(1.09–1.36) 1.24(1.11–1.38) 1.65(1.48–1.83) <0.001
All 2 1.00 1.15(1.02–1.28) 1.10(0.98–1.23) 1.33(1.19–1.49) <0.001
Men1 1.00 1.17(1.01–1.36) 1.13(0.97–1.32) 1.54(1.33–1.78) <0.001
Men2 1.00 1.09(0.93–1.26) 1.01(0.87–1.18) 1.26(1.09–1.47) 0.008
Women1 1.00 1.29(1.09–1.52) 1.40(1.19–1.65) 1.85(1.58–2.16) <0.001
Women2 1.00 1.22(1.03–1.44) 1.23(1.04–1.45) 1.46(1.24–1.73) <0.001
Lymphocytes
Incident diabetes, (men/women) (n/n) 284/233 319/370 442/353 476/469
All 1 1.00 1.10(0.98–1.24) 1.22(1.09–1.37) 1.46(1.31–1.63) <0.001
All 2 1.00 1.06(0.95–1.19) 1.13(1.01–1.26) 1.29(1.15–1.44) <0.001
Men1 1.00 1.02(0.87–1.19) 1.12(0.96–1.30) 1.28(1.10–1.48) <0.001
Men2 1.00 0.99(0.85–1.17) 1.06(0.91–1.23) 1.16(1.00–1.35) 0.026
Women1 1.00 1.20(1.02–1.41) 1.32(1.12–1.56) 1.70(1.45–1.99) <0.001
Women2 1.00 1.13(0.96–1.34) 1.20(1.02–1.42) 1.43(1.22–1.69) <0.001
All values are Hazard ratio (HR) (95%CI), unless otherwise stated.
1HR adjusted for age, sex, BMI and family history of diabetes.
2HR (1) plus adjusted for waist, systolic blood pressure, blood pressure-lowering medication, lipid-lowering medication, prevalent cardiovascular disease,
smoking habits, physical activities, marital status and education level. Cl, conﬁdence interval. MDC, Malmö Diet and Cancer.
doi:10.1371/journal.pone.0148963.t002
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hospital visits in the country and the pharmaceutical register covers all filled prescriptions
from all pharmacies in Sweden since 2005. The HbA1c register covers the population in the city
of Malmö. The relationship between leukocytes and diabetes was largely the same for each of
the data sources. Diabetes can go undetected for several years and individuals that do not seek
medical care will be missed. However, the coverage of the registers is very good and we have no
reason to question the case validity. Lack of information about change of exposure during the
follow-up (e.g. weight change, quitting smoking, new medication, etc.) was another possible
limitation. A further limitation is the potential pleiotropy for the SH2B3missense variant,
which is associated with many traits. Although this would be more relevant in the context of a
positive finding, it could be hypothesized that a pleiotropic effect could attenuate any associa-
tion with diabetes. So-called canalization, i.e., compensatory mechanisms that counterbalance
the effects of the genetic instrument, is another possibility that hypothetically could explain the
negative results for the R262W polymorphism.
Although the leukocyte count significantly increased the model discrimination in terms of
C-statistics, it is uncertain whether measurements of leukocytes could improve prediction of
future diabetes in clinical practice. However, further studies are needed to confirm this. In con-
clusion, increased leukocyte counts are associated with incidence of diabetes. However, the
negative findings for the R262W polymorphism suggest that the associations may not be
causal, although limitations in statistical power and balancing pleiotropic effects cannot be
excluded. Further studies are needed for replication of this finding in other cohorts.
Supporting Information
S1 Table. Quartiles of total leukocytes and diabetes mellitus risk factors of participants in
MDC and MDC-CV in men.
(DOC)
S2 Table. Quartiles of total leukocytes and diabetes mellitus risk factors of participants in
MDC and MDC-CV in women.
(DOC)
S3 Table. Incidence of diabetes mellitus in relation to sex-specific quartiles of total leuko-
cytes and neutrophils in MDC-CV cohort (n = 5 473).
(DOC)
Table 3. Baseline characteristics of the study population divided by alleles (CC, CT, TT) of R262W (N = 24 489).
CC CT TT P for ANOVA
N (%) 6772 (27.7) 12074(49.3) 5643(23.0)
Leukocyte count, (109/L) 6.3±1.7 6.4±2.3 6.5±1.9 <0.001
Sex, men, % 38.3 38.6 39.1 0.680
Age (years) 58.3±7.7 58.0±7.7 58.1±7.6 0.049
BMI (kg/m2) 25.7±3.9 25.6±3.9 25.7±4.0 0.154
Waist (cm) 83.7±12.8 83.6±12.7 83.8±12.9 0.495
Incident diabetes n (per 1000 person-year) 762 (8.0) 1309 (7.7) 644 (8.2) 0.465
Glucose (mmol L−1) (n = 4964) 5.02±0.81 4.99±0.71 4.99±0.74 0.562
HbA1c (%) (n = 4966) 4.84±0.54 4.81±0.48 4.81±0.47 0.219
Insulin* (mIU/l) (n = 4798) 6.0(4.0–9.0) 6.0(4.0–9.0) 6.0(4.0–9.0) 0.067
Values are as means ± standard deviations or %. BMI: body mass index.
*insulin is presented as median and interquartile limits due to skewed distribution.
doi:10.1371/journal.pone.0148963.t003
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